Johnson & Johnson Reports real-world evidence Data for Nemolizumab in Moderate-to-severe plaque psoriasis

Johnson & Johnson today announced real-world evidence results for Nemolizumab in patients with Moderate-to-severe plaque psoriasis. The study demonstrated that Nemolizumab demonstrates favorable safety profile compared to standard of care or placebo. These results provide important insights into the treatment of Moderate-to-severe plaque psoriasis and support the continued development of Nemolizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Nemolizumab was consistent with previous observations, with no new safety signals identified.